Table 3.
Work Productivity and Activity Impairment Questionnaire - Rheumatoid Arthritis (WPAI-RA): impairment of regular activities among all patients at baseline and least-squares mean change from baseline at week 24 and at week 52
| WPAI-RA question administered to all patientsa | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Baseline, Mean (SD) | Week 24, LSM (95% CI) | Week 52, LSM (95% CI) | |||||||
| MTX (N = 210) | Baricitinib 4 mg (N = 159) | Baricitinib 4 mg + MTX (N = 215) | MTX (N = 210) | Baricitinib 4 mg (N = 159) | Baricitinib 4 mg + MTX (N = 215) | MTX (N = 210) | Baricitinib 4 mg (N = 159) | Baricitinib 4 mg + MTX (N = 215) | |
| Percent activity impairment due to RA | 61 (26) | 62 (25) | 59 (25) | − 25 (− 29, − 22) | − 37 (− 40, − 33)*** | − 33 (− 37, − 30)*** | − 29 (− 32, −25) | − 35 (− 38, − 31)* | − 38 (− 42, − 35)*** |
CI confidence interval, LSM least-squares mean, MTX methotrexate, RA rheumatoid arthritis
aData are presented as mean (standard deviation) unless stated otherwise
*p ≤ 0.05; ***p ≤ 0.001 vs. MTX